公开(公告)号：US12122771B2

公开(公告)日：2024-10-22

申请号：US17675696

申请日：2022-02-18

Applicant: HIGH POINT UNIVERSITY

Inventor： Comfort Ahenkan Boateng

IPC: C07D417/14 ,  A61P25/30 ,  C07D417/06

CPC classification number: C07D417/14 ,  A61P25/30 ,  C07D417/06

Abstract: The disclosure provides compounds which exhibit dopamine receptor antagonist activity and which may be useful as therapeutic agents for the treatment of diseases and disorders associated with dopamine receptors. Also provided are methods for the preparation of such compounds, pharmaceutical compositions comprising the disclosed compounds, and methods for treating diseases or disorders with such compounds or pharmaceutical compositions.

公开(公告)号：US11739054B2

公开(公告)日：2023-08-29

申请号：US17129712

申请日：2020-12-21

Applicant: MOLECULAR EXPRESS, INC.

Inventor： Kim Janda ,  Sam On Ho ,  Gary Fujii

IPC: C07C233/54 ,  A61P25/30 ,  A61K39/00 ,  A61K39/385

CPC classification number: C07C233/54 ,  A61K39/0013 ,  A61K39/385 ,  A61P25/30 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/6012 ,  A61K2039/6037 ,  A61K2039/627

Abstract: The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.

公开(公告)号：US11707089B2

公开(公告)日：2023-07-25

申请号：US16801780

申请日：2020-02-26

Applicant: Altria Client Services LLC

Inventor： Yossef Raichman

IPC: A24F47/00 ,  A24F40/42 ,  A24F40/46 ,  A24F40/40 ,  A24F40/57 ,  A24F40/50 ,  A61M11/04 ,  A61M15/00 ,  A61P25/36 ,  A61P27/06 ,  A61P25/30 ,  A61P43/00 ,  A61P11/06 ,  A61P25/18 ,  A61P25/08 ,  A61P29/00 ,  A61P1/08 ,  A61K9/00 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61M15/06 ,  A24F40/20 ,  A24F40/60 ,  A24F40/95 ,  A61M16/00

CPC classification number: A24F40/42 ,  A24F40/40 ,  A24F40/46 ,  A24F40/50 ,  A24F40/57 ,  A61K9/007 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61M11/042 ,  A61M15/00 ,  A61M15/003 ,  A61M15/06 ,  A61P1/08 ,  A61P11/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/30 ,  A61P25/36 ,  A61P27/06 ,  A61P29/00 ,  A61P43/00 ,  A24F40/20 ,  A24F40/60 ,  A24F40/95 ,  A61M15/002 ,  A61M15/0021 ,  A61M2016/0024 ,  A61M2205/3334 ,  A61M2205/3368 ,  A61M2205/8206

Abstract: Apparatus and methods are described for use with a portion of plant material that includes at least one active ingredient. A vaporizing unit includes a heating element configured to heat the plant material, and a sensor configured to detect an indication of airflow rate through the vaporizing unit. Control circuitry is configured to receive an indication of the airflow rate through the vaporizing unit, and, in response thereto, to determine a smoking profile that is desired by the user. The control circuitry drives the heating element to vaporize the active ingredient of the plant material by heating the plant material according to the determined smoking profile. The control circuitry dynamically updates the smoking profile in response to changes in airflow rate over the course of a smoking session. Other applications are also described.

公开(公告)号：US20230174613A1

公开(公告)日：2023-06-08

申请号：US18047734

申请日：2022-10-19

Applicant: Rutgers, The State University of New Jersey

Inventor： Hannah E. BOWREY ,  Gary ASTON-JONES

IPC: C07K14/705 ,  A61K45/06 ,  A61P25/00 ,  A61P9/10 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K9/00 ,  A61K31/5513 ,  C12N15/86

CPC classification number: C07K14/705 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/5513 ,  A61K45/06 ,  A61P9/10 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2830/008

Abstract: Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.

公开(公告)号：US20190231826A1

公开(公告)日：2019-08-01

申请号：US16383612

申请日：2019-04-14

Applicant: Phytopharma International Ltd.

Inventor： Amit Dov AVIDOV ,  Ilan BEN SIMON

IPC: A61K35/644 ,  A61K9/00 ,  A23K20/158 ,  A23L21/25 ,  A61P21/00 ,  A61P27/06 ,  A61P25/28 ,  A61P25/30 ,  A61P11/06 ,  A61P25/32 ,  A61P19/02 ,  A61P25/04 ,  A61P25/18 ,  A61P25/24 ,  A61P25/08 ,  A61P29/00 ,  A61P1/08 ,  A61P25/06 ,  A61K31/352 ,  A61K36/185 ,  A61K31/05 ,  A23K50/90 ,  A23K20/163

CPC classification number: A61K35/644 ,  A23K20/158 ,  A23K20/163 ,  A23K50/90 ,  A23L21/25 ,  A23V2002/00 ,  A61K9/0056 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61P1/08 ,  A61P11/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/32 ,  A61P27/06 ,  A61P29/00

Abstract: A bee ingestible composition comprising a bee food base and THC and/or CBD is provided. Also provided are methods of producing honey, honey obtainable by these methods and uses of same.

公开(公告)号：US20190216753A1

公开(公告)日：2019-07-18

申请号：US16336418

申请日：2017-09-26

Applicant: Qingdao Primedicine Pharmaceutical Company, Ltd.

Inventor： Yu Tian Wang ,  Peter Axerio-Cilies

IPC: A61K31/166 ,  A61P25/28 ,  A61P25/30 ,  A61P25/24 ,  A61K31/655 ,  A61K31/165

CPC classification number: A61K31/166 ,  A61K31/165 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/655 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

Abstract: This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.

公开(公告)号：US20180327422A1

公开(公告)日：2018-11-15

申请号：US15774407

申请日：2016-11-15

Applicant: LABORATORIOS DEL DR. ESTEVE S.A.

Inventor： Marina VIRGILI-BERNADO ,  Carmen ALMANSA-ROSALES ,  Carlos ALEGRET-MOLINA

IPC: C07D498/10 ,  A61P25/30

CPC classification number: C07D498/10 ,  A61P25/30

Abstract: The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular against drug abuse and addiction.

公开(公告)号：US20180319841A1

公开(公告)日：2018-11-08

申请号：US15771078

申请日：2016-11-30

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Jae Young SEONG ,  Jong-Ik HWANG ,  Dong-Hoon KIM ,  Gi Hoon SON ,  Yoo-Na LEE ,  Seongsik YUN ,  Arfaxad REYES-ALCARAZ

IPC: C07K7/08 ,  A61K9/19 ,  A61K9/00

CPC classification number: C07K7/08 ,  A61K9/00 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61P25/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.

公开(公告)号：US20180170908A1

公开(公告)日：2018-06-21

申请号：US15839901

申请日：2017-12-13

Applicant: Pfizer Inc.

Inventor： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew S. Dowling ,  David Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC: C07D401/14 ,  C07D471/04 ,  C07D405/14 ,  C07D413/14 ,  A61P3/10 ,  A61P25/28 ,  A61P25/02 ,  A61P13/12 ,  A61P43/00 ,  A61P3/04 ,  A61P1/16 ,  A61P9/10 ,  A61P19/02 ,  A61P25/16 ,  A61P19/06 ,  A61P15/10 ,  A61P17/06 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/30

CPC classification number: C07D401/14 ,  A61K31/4545 ,  A61K31/496 ,  A61P1/00 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20180155333A1

公开(公告)日：2018-06-07

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku KAMEI ,  Yasuyoshi ARIKAWA ,  Tomohiro OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Takashi MIKI ,  Jinichi YONEMORI ,  Yuya OGURO ,  Takahiro SUGIMOTO ,  Masaki SETO ,  Goushi NISHIDA ,  Makoto KAMATA ,  Hiroshi IMOTO

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D409/14 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

CPC classification number: C07D413/14 ,  A61K31/553 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.